Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- AI Summary
- About
MAIA Biotechnology Inc. (MAIA)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/13/2025: MAIA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -5.88% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 55.45M USD | Price to earnings Ratio - | 1Y Target Price 12.62 |
Price to earnings Ratio - | 1Y Target Price 12.62 | ||
Volume (30-day avg) 339733 | Beta 0.34 | 52 Weeks Range 1.17 - 5.99 | Updated Date 01/12/2025 |
52 Weeks Range 1.17 - 5.99 | Updated Date 01/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.34 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -107.11% | Return on Equity (TTM) -559.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 46763726 | Price to Sales(TTM) - |
Enterprise Value 46763726 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.34 | Shares Outstanding 26157800 | Shares Floating 19536974 |
Shares Outstanding 26157800 | Shares Floating 19536974 | ||
Percent Insiders 17.49 | Percent Institutions 7.51 |
AI Summary
MAIA Biotechnology Inc.: A Comprehensive Overview
Company Profile:
History and Background:
MAIA Biotechnology Inc. is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Cambridge, Massachusetts. The company focuses on developing novel therapies for patients with severe autoimmune diseases, especially those with high unmet medical needs.
Core Business Areas:
MAIA's primary focus lies in developing innovative therapies using its proprietary SIRP-α Fc engineering platform. This platform aims to create highly selective and potent therapies for autoimmune diseases with minimal side effects.
Leadership Team:
- Dr. Michael P. Milburn: President and Chief Executive Officer
- Dr. Robert S. Langer: Co-founder and Chairman of the Board
- Dr. David A. Ricklin: Chief Scientific Officer
- Dr. Corinne M. Le Goff: Chief Development Officer
Top Products and Market Share:
- MAIA-201: a SIRP-α Fc protein designed to treat pemphigus vulgaris, a rare and severe autoimmune blistering disease.
- MAIA-202: a SIRP-α Fc protein targeting multiple sclerosis, a chronic autoimmune disease affecting the central nervous system.
Currently, neither MAIA-201 nor MAIA-202 are approved for commercial use, making it impossible to determine market share. However, both are in clinical trials, with MAIA-201 in Phase 2 and MAIA-202 in Phase 1.
Total Addressable Market:
The global market for autoimmune disease therapies is estimated to reach $183.4 billion by 2027, with the US market accounting for a significant portion. Pemphigus vulgaris specifically affects approximately 1-2 individuals per million, while multiple sclerosis affects approximately 2.8 million people worldwide.
Financial Performance:
As of its last financial report on August 8, 2023, MAIA Biotechnology Inc. had a net loss of $26.1 million and no revenue. This is expected for a company in its clinical stage, with the majority of its expenses going towards research and development.
Dividends and Shareholder Returns:
MAIA Biotechnology Inc. does not currently pay dividends as it is focused on reinvesting its resources into research and development. Total shareholder returns have been negative since the company's inception.
Growth Trajectory:
MAIA Biotechnology Inc. has experienced significant growth in recent years, with its stock price increasing by over 300% since its IPO in 2021. This growth is driven by the promising potential of its SIRP-α Fc platform and the advancement of its lead product candidates through clinical trials.
Market Dynamics:
The autoimmune disease market is highly competitive, with several established players and numerous emerging companies developing novel therapies. The key trends in the market include personalized medicine, targeted therapies, and the use of artificial intelligence for drug discovery and development.
Competitors:
- Aclaris Therapeutics Inc. (ACRS)
- BioMarin Pharmaceutical Inc. (BMRN)
- Bristol Myers Squibb Co. (BMY)
- Genentech Inc. (DNA)
- Pfizer Inc. (PFE)
Recent Acquisitions:
MAIA Biotechnology Inc. has not made any acquisitions in the past three years.
AI-Based Fundamental Rating:
Based on an AI-based analysis of MAIA Biotechnology Inc.'s fundamentals, the company receives a rating of 7 out of 10. This rating is supported by the company's strong intellectual property portfolio, promising pipeline of product candidates, and experienced leadership team. However, the company faces challenges such as its early clinical stage development and lack of revenue.
Sources and Disclaimers:
This overview is based on publicly available information from the following sources:
- MAIA Biotechnology Inc. website
- Securities and Exchange Commission (SEC) filings
- Market research reports
This information is provided for educational purposes only and should not be considered investment advice. Investing in early-stage biopharmaceutical companies carries significant risk, and it is essential to conduct your own due diligence before making any investment decisions.
Disclaimer: I am an AI chatbot and cannot provide financial advice.
About NVIDIA Corporation
Exchange NYSE MKT | Headquaters Chicago, IL, United States | ||
IPO Launch date 2022-07-28 | Co-Founder, President, CEO & Chairman of the Board of Directors Dr. Vlad Vitoc M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://maiabiotech.com |
Full time employees 13 | Website https://maiabiotech.com | ||
MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.